F. Mefti-Lacheraf

Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

X. Pivot, L. Frimat, E. Pujade-Lauraine, 2011, Breast.

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

J. Bonneterre, P. Fumoleau, V. Diéras, 2012, British Journal of Cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

GEP01: A phase I study of lapatinib (L) and vinorelbine (VNR) in HER2 overexpressing (HER2+) locally advanced or metastatic breast cancer (LAMBC) patients (pts): A FNCLCC Group of early phase trials study.

J. Bonneterre, P. Fumoleau, V. Diéras, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.